4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Condition(s):Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast CancerLast Updated:July 21, 2015Completed
Hide Studies Not Open or Pending
Condition(s):Ductal Breast Carcinoma in Situ; Estrogen Receptor-positive Breast CancerLast Updated:July 21, 2015Completed
Condition(s):Ductal Breast Carcinoma In Situ; HER2/Neu PositiveLast Updated:April 20, 2018Completed
Condition(s):Ductal Breast Carcinoma in SituLast Updated:February 6, 2020Recruiting
Condition(s):Intraductal Carcinoma and Lobular Carcinoma in SituLast Updated:August 25, 2016Completed
Condition(s):Breast CancerLast Updated:April 14, 2020Recruiting
Condition(s):Breast CancerLast Updated:May 17, 2017Completed
Condition(s):Breast CancerLast Updated:December 4, 2020Completed
Condition(s):Ductal Carcinoma in SituLast Updated:April 9, 2020Terminated
Condition(s):Breast CancerLast Updated:February 25, 2013Terminated
Condition(s):Breast CancerLast Updated:November 21, 2014Completed
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.